When your pharmacist hands you a generic pill instead of the brand-name version you asked for, they’re not just saving you money-they’re following a strict legal system backed by the FDA. This system is called Therapeutic Equivalency (TE) Codes, and it’s the reason some generics can be swapped freely, while others can’t-even if they contain the same active ingredient.
What Are TE Codes and Why Do They Matter?
Therapeutic Equivalency Codes are alphanumeric labels assigned by the FDA to prescription drugs that have multiple versions on the market. These codes tell pharmacists and doctors whether a generic drug is considered clinically interchangeable with the original brand-name drug. It’s not about price. It’s not about marketing. It’s about science and law. The system was created in 1984 under the Hatch-Waxman Act, which aimed to speed up access to affordable generics without sacrificing patient safety. Since then, the FDA has published these evaluations monthly in the Approved Drug Products with Therapeutic Equivalence Evaluations-better known as the Orange Book. As of October 2023, it lists over 14,000 drug products with TE ratings. If a drug has an ‘A’ code, it means the FDA has confirmed that the generic works just like the brand-name version. You can swap it without worry. If it has a ‘B’ code, the FDA says there’s uncertainty-maybe the drug doesn’t absorb the same way, or the delivery system is too complex to prove equivalence. In those cases, substitution isn’t allowed under the law.The Letter System: A, B, and What Comes After
The first letter in the TE code is the most important. ‘A’ means therapeutically equivalent. ‘B’ means not equivalent-or at least, not proven to be. But it gets more detailed. The second character adds nuance:- AA: Immediate-release oral drugs with no bioequivalence issues. These are the most common generics-like generic ibuprofen or metformin.
- AB: Products that once had bioequivalence concerns but later proved equivalent through additional testing. This is how many complex generics get approved after initial rejection.
- BC: Extended-release formulations where bioequivalence is hard to prove. These often carry a ‘B’ rating because the drug releases slowly over time, and small differences in formulation can change how it works in the body.
- BT: Topical products like creams or gels. Even if they look identical, skin absorption can vary, so most are still rated ‘B’.
- BN: Nebulized aerosols. These require precise particle size and delivery, making equivalence testing extremely difficult.
- BX: No data available. These are new generics or drugs with insufficient studies to judge.
How State Laws Turn FDA Codes into Legal Rules
The FDA sets the scientific standard, but state pharmacy boards decide what happens at the counter. All 50 states use the Orange Book as their official reference for substitution. But each state has its own law spelling out when substitution is allowed. In California, for instance, the law says pharmacists can only substitute if the drug has an ‘A’ code. In Texas, substitution is allowed unless the prescriber writes “dispense as written.” In New York, pharmacists must check the most current Orange Book edition before swapping any generic. The key point: the FDA doesn’t force substitution. It only says whether it’s scientifically safe. The decision to allow it is up to the state-and often, the prescriber. This creates a patchwork. A drug might be legally substitutable in Florida but not in Massachusetts, even if the TE code is the same. That’s why pharmacists must stay updated on both federal ratings and state regulations.
Why Some Generics Still Have ‘B’ Codes
You might wonder: if a generic is FDA-approved, why isn’t it automatically interchangeable? The answer lies in complexity. Simple pills are easy to test. But drugs that deliver medication slowly, through the skin, via inhalation, or as a liquid suspension? Those are harder. Take topical creams. Two creams may contain the same amount of steroid, but if one uses a different emulsifier, it might absorb slower-or not at all. The FDA doesn’t have a perfect test for that yet. So until they do, those products get a ‘B’ rating. The same goes for complex inhalers or injectables. Even small changes in particle size or viscosity can affect how the drug behaves in the body. In 2022, over 3,400 products had ‘B’ codes-nearly a quarter of all rated drugs. Most of them fall into these hard-to-test categories. A 2021 study in the Journal of Generic Medicines found that 94.7% of all generic prescriptions filled were for ‘A’-rated drugs. That means only 5.3% involved products with unresolved equivalence questions. But those 5.3% are the ones causing the most confusion-and the most legal risk for pharmacists.The Economic Impact and Why It Matters to You
The TE code system isn’t just about safety. It’s about billions of dollars. Since 1995, generic drugs approved under this system have saved the U.S. healthcare system over $1.7 trillion. In 2022 alone, ‘A’-rated generics saved $298 billion. That’s money that goes back into patients’ pockets, insurance premiums, and hospital budgets. But here’s the catch: drugs with ‘B’ codes are rarely dispensed as generics. Why? Because pharmacists are afraid to substitute them. A 2022 survey by the Generic Pharmaceutical Association found that 68% of pharmacists avoid swapping ‘BT’ (topical) or ‘BN’ (nebulized) products-even when the law allows it-because they’re unsure about clinical outcomes. That means patients pay more. Brand-name drugs cost 3 to 10 times more than generics. If a ‘B’-rated generic sits on the shelf because no one’s willing to use it, the patient ends up paying for the brand.
What’s Changing in 2026?
The FDA knows the ‘B’ code backlog is a problem. In 2023, they launched the Complex Generic Drug Initiative to reduce the number of ‘B’-rated products from 24.3% to under 15% by 2027. They’re investing $28.7 million through the GDUFA III program to develop better testing methods for complex delivery systems. New guidance documents released in August 2023 clarify that minor changes in inactive ingredients won’t automatically disqualify a drug from an ‘A’ rating-if the active ingredient performs the same. The Orange Book is also going digital. Since January 2023, it’s been available via API, meaning electronic health records and pharmacy systems can pull real-time TE code data. This reduces human error and helps pharmacists make faster, safer decisions. The goal? More generics. Lower prices. Same safety. And fewer patients stuck paying for brand names because the system didn’t trust the generic.What Should You Do as a Patient?
You don’t need to memorize TE codes. But you should know this:- If your pharmacist switches your prescription to a generic, it’s because the FDA says it’s safe to do so.
- If you’re told a generic isn’t available, ask: “Is it because of the TE code?” If they say yes, and it’s a ‘B’ code, you might want to ask your doctor if there’s an alternative with an ‘A’ rating.
- If you notice a change in how a generic works-side effects, effectiveness, timing-tell your pharmacist and doctor. It could be a formulation issue.
Can a pharmacist substitute a generic drug without asking me?
Yes, in most cases-if the drug has an ‘A’ therapeutic equivalency code and your state allows substitution. Pharmacists are required to follow state laws, and most states permit substitution unless the prescriber writes “dispense as written.” But they must check the current Orange Book to confirm the TE code before swapping.
Why does my generic look different from the brand name?
By law, generic drugs can look different in color, shape, or size because inactive ingredients (like dyes or fillers) aren’t regulated for appearance. What matters is that the active ingredient, strength, dosage form, and bioavailability match the brand. The FDA’s TE code confirms this. If the code is ‘A,’ the difference in appearance doesn’t affect how the drug works.
Are over-the-counter (OTC) drugs assigned TE codes?
No. TE codes only apply to prescription drugs approved under Section 505 of the Federal Food, Drug, and Cosmetic Act. OTC medications like ibuprofen or loratadine are regulated under different standards and aren’t evaluated for therapeutic equivalence in the Orange Book.
Can a drug’s TE code change after it’s approved?
Yes. If new data shows a generic product no longer meets bioequivalence standards-or if it’s proven equivalent after initial rejection-the FDA can update its TE code. For example, a product might start as ‘BX’ (insufficient data) and later become ‘AB’ after additional studies. The Orange Book is updated monthly to reflect these changes.
Do TE codes apply to biologics or biosimilars?
No. TE codes are only for small-molecule chemical drugs approved under ANDAs or 505(b)(2) applications. Biologics-like insulin, monoclonal antibodies, or vaccines-are regulated under a different pathway and have their own biosimilar interchangeability standards, which are determined by the FDA separately.
Written by Mallory Blackburn
View all posts by: Mallory Blackburn